COPS5 Conferred the Platinum Resistance in Epithelial Ovarian Cancer

Overview

Journal Curr Issues Mol Biol

Publisher MDPI

Specialty Molecular Biology

Date 2022 Sep 22

PMID 36135183

Authors

Hongqin Zhang

Tianqing Yan

Ailing Zhong

Lin Guo

Renquan Lu

Affiliations

Soon will be listed here.

Abstract

Development of platinum resistance is one of the major causes of epithelial ovarian cancer (EOC) treatment failure. COP9 signalosome subunit 5 (COPS5) was found to take part in the progression of EOC in our previous study. Herein, we aim to uncover the potential utility of COPS5 in EOC chemoresistance. COPS5 levels were analyzed to define clinic pathologic correlates using a matched tissue microarray and online datasets. The effect of COPS5 inhibition by the lentivirus-mediated short hairpin RNA on cell viability, proliferation and migration was accessed in vitro and in vivo. Results showed that COPS5 was upregulated in patients after platinum resistance. Kaplan-Meier survival curves revealed that COPS5 overexpression was correlated with shorter PFS and OS. COPS5 downregulation inhibited the cell proliferation, migration, and reduced the sensitivity of EOC to platinum. Overall, our data indicated that COPS5 inhibition might represent a new therapeutic strategy for overcoming platinum resistance in patients with EOC.

Citing Articles

A novel CSN5/CRT O-GlcNAc/ER stress regulatory axis in platinum resistance of epithelial ovarian cancer.

Yan T, Ma X, Zhou K, Cao J, Tian Y, Zheng H Int J Biol Sci. 2024; 20(4):1279-1296.

PMID: 38385070 PMC: 10878149. DOI: 10.7150/ijbs.89700.

Exploration of Diagnostic Deubiquitinating Enzymes in Endometriosis and Its Immune Infiltration.

Yang X, Yan K, Zhan Q, Chen H, Pei C, Zhu L Biochem Genet. 2024; 62(6):4359-4379.

PMID: 38302849 DOI: 10.1007/s10528-023-10653-w.

References

Ishida S, Lee J, Thiele D, Herskowitz I . Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci U S A. 2002; 99(22):14298-302. PMC: 137878. DOI: 10.1073/pnas.162491399. View

Yang-Hartwich Y, Soteras M, Lin Z, Holmberg J, Sumi N, Craveiro V . p53 protein aggregation promotes platinum resistance in ovarian cancer. Oncogene. 2014; 34(27):3605-16. DOI: 10.1038/onc.2014.296. View

Menyhart O, Fekete J, Gyorffy B . Gene Expression Indicates Altered Immune Modulation and Signaling Pathway Activation in Ovarian Cancer Patients Resistant to Topotecan. Int J Mol Sci. 2019; 20(11). PMC: 6600443. DOI: 10.3390/ijms20112750. View

Lu M, Chen X, Xiao J, Xiang J, Yang L, Chen D . FOXO3a Reverses the Cisplatin Resistance in Ovarian Cancer. Arch Med Res. 2018; 49(2):84-88. DOI: 10.1016/j.arcmed.2018.04.014. View

Cadoni E, Valletta E, Caddeo G, Isaia F, Cabiddu M, Vascellari S . Competitive reactions among glutathione, cisplatin and copper-phenanthroline complexes. J Inorg Biochem. 2017; 173:126-133. DOI: 10.1016/j.jinorgbio.2017.05.004. View

Yan D, Pomicter A, Tantravahi S, Mason C, Senina A, Ahmann J . Nuclear-Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis. Clin Cancer Res. 2018; 25(7):2323-2335. PMC: 6445677. DOI: 10.1158/1078-0432.CCR-18-0959. View

Gyorffy B, Lanczky A, Szallasi Z . Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. Endocr Relat Cancer. 2012; 19(2):197-208. DOI: 10.1530/ERC-11-0329. View

Chang S, Hodeib M, Chang J, Bristow R . Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis. Gynecol Oncol. 2013; 130(3):493-8. DOI: 10.1016/j.ygyno.2013.05.040. View

ODwyer P, Hamilton T, Lacreta F, Gallo J, Kilpatrick D, Halbherr T . Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer. J Clin Oncol. 1996; 14(1):249-56. DOI: 10.1200/JCO.1996.14.1.249. View

10.

Criscuolo D, Avolio R, Calice G, Laezza C, Paladino S, Navarra G . Cholesterol Homeostasis Modulates Platinum Sensitivity in Human Ovarian Cancer. Cells. 2020; 9(4). PMC: 7226826. DOI: 10.3390/cells9040828. View

11.

Li M, Balch C, Montgomery J, Jeong M, Chung J, Yan P . Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer. BMC Med Genomics. 2009; 2:34. PMC: 2712480. DOI: 10.1186/1755-8794-2-34. View

12.

. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474(7353):609-15. PMC: 3163504. DOI: 10.1038/nature10166. View

13.

Moore K, Martin L, OMalley D, Matulonis U, Konner J, Vergote I . A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer. Future Oncol. 2017; 14(2):123-136. DOI: 10.2217/fon-2017-0379. View

14.

Kumar S, Tchounwou P . Molecular mechanisms of cisplatin cytotoxicity in acute promyelocytic leukemia cells. Oncotarget. 2015; 6(38):40734-46. PMC: 4747365. DOI: 10.18632/oncotarget.5754. View

15.

Siegel R, Miller K, Fuchs H, Jemal A . Cancer Statistics, 2021. CA Cancer J Clin. 2021; 71(1):7-33. DOI: 10.3322/caac.21654. View

16.

Zhang H, Zhong A, Sun J, Chen M, Xie S, Zheng H . COPS5 inhibition arrests the proliferation and growth of serous ovarian cancer cells via the elevation of p27 level. Biochem Biophys Res Commun. 2017; 493(1):85-93. DOI: 10.1016/j.bbrc.2017.09.070. View

17.

Lu R, Hu X, Zhou J, Sun J, Zhu A, Xu X . COPS5 amplification and overexpression confers tamoxifen-resistance in ERα-positive breast cancer by degradation of NCoR. Nat Commun. 2016; 7:12044. PMC: 4932188. DOI: 10.1038/ncomms12044. View

18.

Liu G, Claret F, Zhou F, Pan Y . Jab1/COPS5 as a Novel Biomarker for Diagnosis, Prognosis, Therapy Prediction and Therapeutic Tools for Human Cancer. Front Pharmacol. 2018; 9:135. PMC: 5835092. DOI: 10.3389/fphar.2018.00135. View

19.

Zhong A, Zhang H, Xie S, Deng M, Zheng H, Wang Y . Inhibition of MUS81 improves the chemical sensitivity of olaparib by regulating MCM2 in epithelial ovarian cancer. Oncol Rep. 2018; 39(4):1747-1756. DOI: 10.3892/or.2018.6229. View

20.

Lu R, Sun M, Feng J, Gao X, Guo L . Myofibrillogenesis regulator 1 (MR-1) is a novel biomarker and potential therapeutic target for human ovarian cancer. BMC Cancer. 2011; 11:270. PMC: 3132198. DOI: 10.1186/1471-2407-11-270. View